Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1031 to 1040 of 2733 total matches.
A New Botulinum Toxin (Xeomin) for Cervical Dystonia and Blepharospasm
The Medical Letter on Drugs and Therapeutics • Nov 15, 2010 (Issue 1351)
for treatment of cervical
dystonia. Botox is also approved for treatment of blepharospasm.
1
CERVICAL ...
The FDA has approved incobotulinumtoxinA (Xeomin –
Merz) for treatment of cervical dystonia and blepharospasm
in adults. It has been commercially available
in Germany since 2005. Several formulations of
botulinum toxin type A (Botox; Dysport) and type B
(Myobloc) are already marketed for treatment of cervical
dystonia. Botox is also approved for treatment of blepharospasm.
Mifepristone (Korlym) for Cushing's Syndrome
The Medical Letter on Drugs and Therapeutics • Jun 11, 2012 (Issue 1392)
to glucocorticoid receptors
and, to a lesser extent, androgen receptors.
Table 1. Pharmacology
Formulation 300-mg ...
The FDA has approved the antiprogestin mifepristone
(Korlym – Corcept Therapeutics) for control of hyperglycemia
secondary to hypercortisolism in adults with
endogenous Cushing’s syndrome who have type 2 diabetes/
glucose intolerance and have not responded to,
or are not candidates for, surgery. Formerly known as
RU 486, mifepristone is also available in a lower
strength as Mifeprex for use in terminating an early
intrauterine pregnancy.
A New Scorpion Antivenom
The Medical Letter on Drugs and Therapeutics • Jun 25, 2012 (Issue 1393)
17,000 scorpion
stings are reported every year in the US.1 Arizona
alone reports more than 10,000 ...
Anascorp (Rare Disease Therapeutics), an intravenously
administered antivenom derived from horse
serum, has been approved by the FDA for treatment of
clinical signs of scorpion envenomation.
Renal Sympathetic Denervation for Hypertension
The Medical Letter on Drugs and Therapeutics • Jul 09, 2012 (Issue 1394)
Publication
CLINICAL STUDIES — The first study of the
cathether-based procedure (Symplicity HTN-1)
included ...
Renal sympathetic denervation is under investigation as
a therapeutic option for hypertension that has not
responded to ≥3 antihypertensive drugs (resistant
hypertension).
Pimavanserin (Nuplazid) for Parkinson's Disease Psychosis
The Medical Letter on Drugs and Therapeutics • Jun 06, 2016 (Issue 1496)
% of patients with
Parkinson’s disease.1 Low doses of clozapine
(Clozaril, and others) have been effective ...
The FDA has approved the atypical antipsychotic
pimavanserin (Nuplazid – Acadia) for treatment
of hallucinations and delusions associated with
Parkinson's disease. It is the first drug to be approved
in the US for this indication.
Dapagliflozin (Farxiga) - A New Indication for Heart Failure
The Medical Letter on Drugs and Therapeutics • Jun 29, 2020 (Issue 1601)
diabetes and established cardiovascular
disease (CVD) or multiple cardiovascular risk factors,1,2
has now ...
The sodium-glucose cotransporter 2 (SGLT2)
inhibitor dapagliflozin (Farxiga), which was
initially approved by the FDA for treatment of
type 2 diabetes and then to reduce the risk of hospitalization for HF in adults who have type 2 diabetes and established cardiovascular disease
(CVD) or multiple cardiovascular risk factors, has
now been approved for a third indication: to reduce
the risk of cardiovascular death and hospitalization
for heart failure (HF) in patients with heart failure
with reduced ejection fraction (with or without
type 2 diabetes). It is the first SGLT2 inhibitor to...
In Brief: Pfizer/BioNTech COVID-19 Vaccine Authorized for Children 5-11 Years Old
The Medical Letter on Drugs and Therapeutics • Nov 29, 2021 (Issue 1638)
years old.1 The original formulation
of Comirnaty (30 mcg/0.3 mL) is FDA-licensed for
use in persons ...
The FDA has issued an Emergency Use Authorization
(EUA) for a lower-strength (10 mcg/0.2 mL) formulation
of the mRNA-based COVID-19 vaccine
manufactured by Pfizer/BioNTech (Comirnaty) for use
in children 5-11 years old. The original formulation
of (Comirnaty) (30 mcg/0.3 mL) is FDA-licensed for
use in persons ≥16 years old and available under an
EUA for use in adolescents 12-15 years old.
Hemgenix - A Gene Therapy for Hemophilia B
The Medical Letter on Drugs and Therapeutics • Jan 23, 2023 (Issue 1668)
annualized
bleeding rate (ABR) 7-18 months post-infusion was
1.9, compared to 4.1 during the 6-month lead ...
Etranacogene dezaparvovec-drlb (Hemgenix – CSL
Behring), an adeno-associated virus vector-based
gene therapy, has been approved by the FDA for
treatment of hemophilia B in adults who currently
receive factor IX prophylaxis therapy or have had
life-threatening or repeated, serious, spontaneous
bleeding episodes. It is the first gene therapy to be
approved in the US for this indication.
Med Lett Drugs Ther. 2023 Jan 23;65(1668):9-10 doi:10.58347/tml.2023.1668a | Show Introduction Hide Introduction
Talazoparib (Talzenna) for Prostate Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023 (Issue 1682)
in another HR gene.
Table 1. Pharmacology
Class Poly(ADP-ribose) polymerase (PARP)
inhibitor
Formulation ...
The oral poly(ADP-ribose) polymerase (PARP)
inhibitor talazoparib (Talzenna – Pfizer) has been
approved by the FDA for use in combination with the
androgen receptor blocker enzalutamide (Xtandi) for
treatment of adults with homologous recombination
repair (HRR) gene-mutated metastatic castration-resistant
prostate cancer (mCRPC). The drug has
been available since 2018 for treatment of deleterious
or suspected deleterious germline BRCA-mutated
(gBRCAm), HER2-negative locally advanced or
metastatic breast cancer.
Med Lett Drugs Ther. 2023 Aug 7;65(1682):e134-5 doi:10.58347/tml.2023.1682e | Show Introduction Hide Introduction
Cholesterol Rethink for High-Risk Patients
The Medical Letter on Drugs and Therapeutics • May 10, 2004 (Issue 1182)
% in the atorvastatintreated patients, who now had a median LDL cholesterol of 62 mg/dL (1.60 mmol/L), a relative risk ...
The recent "PROVE IT" trial in patients with coronary heart disease showed clinical benefits associated with reducing LDL cholesterol concentrations lower than the 100 mg/dL (2.59 mmol/L) or less that had been considered optimal.
